Product Description

EIA for the quantitative determination of ß-amyloid(1-42) in human cerebrospinal fluid (CSF) – a diagnostic marker of Alzheimer’s disease

Alzheimer’s, the most common form of dementia, is a neurodegenerative disorder histologically characterized by the accumulation of intracellular neurofibrillary tangles and extracellular amyloid plaques throughout the cortical and limbic brain regions. The ultrastructure of neurofibrillary tangles is made up of paired helical filaments composed mainly of abnormally hyperphosphorylated TAU protein (Phospho-TAU). The major
components of the amyloid deposits are the 40- and 42-amino acid-long β-amyloid peptides, which are derived from integral membrane-bound amyloid precursor protein.

The INNOTEST β-AMYLOID(1-42) is a solid-phase enzyme immunoassay in which the amyloid peptide is captured by a first monoclonal antibody, 21F12 (IgG2a). CSF samples are added and incubated with a biotinylated antibody, 3D6 (IgG2b). This antigen-antibody complex is then detected by a peroxidase-labeled streptavidin. After addition of substrate working solution, samples will develop a color. The colour intensity is a measure for the amount of human β-amyloid(1-42) protein in the sample.

 

Product Details

Manufacturer Fujirebio
Unit 96 tests
Code 81576
For sale in GBR NIR
Launch Diagnostics is a licensed reseller and distributor of INNOTESTTM ß-AMYLOID(1-42)

Launch Diagnostics is one of the major independent distributors in the U.K, providing high quality diagnostic reagents and instrumentation from world leading manufacturer’s to the Health Services of the United Kingdom, France, Belgium, Netherlands, Luxemburg and North Africa and to the Republic of Ireland through ACCUSAY Diagnostics.

Offering a large portfolio of diagnostic kits, laboratory instrumentation and services, our product range has expanded over the years to include a comprehensive range of EIA, single test devices, serology products, molecular assays and instrumentation.

Neurodegeneration